Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the pharmacokinetic profile of micafungin
administered to neonates suffering from systemic candidiasis. This study will also evaluate
the proportion of success and of failure of the therapy with micafungin among treated
neonates and will identify a conversion factor to relate plasma levels of micafungin into
capillary and venous blood measured through blood samples from the heel and from a peripheral
vein, collected simultaneously. Safety of micafungin in neonates will also be assessed.